Is STE a Buy or a Sell? The Bull and Bear Case (2026)

Last updated July 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for STERIS plc (STE) rests on Recurring consumables and service, not equipment sales: Most of what STERIS books each quarter is not a machine. The bear case rests on ethylene oxide is the exposure that separates STERIS from an ordinary medical equipment name. Analysts covering it publish targets from $232.00 to $280.00 against a $239.15 price, so even the professionals disagree by 18% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

STERIS plc makes the equipment, chemistries and services that keep hospital operating rooms and medical device production sterile. Three segments carry the business. Healthcare, roughly ~70% of revenue, sells sterilizers, washers, surgical tables, endoscopy reprocessing systems and the consumables and service contracts that follow them into hospitals. Applied Sterilization Technologies (AST), close to ~20% of revenue, runs contract sterilization facilities that gamma-irradiate, e-beam or ethylene oxide treat devices for manufacturers before those devices ship. Life Sciences, near ~10%, supplies cleaning chemistries, small sterilizers and validation services to pharmaceutical producers. Legally the parent is an Irish plc, operationally the company runs out of Mentor, Ohio, and the ordinary shares trade on the NYSE inside the S&P 500. Headcount is roughly ~17,900. The investment picture rests on installed base rather than on new orders. A sterilizer sold today drags decades of chemistries, filters, service visits and replacement parts behind it, which is why STERIS grew revenue ~9% in fiscal 2026 to ~$5.9 billion and guided fiscal 2027 to another ~7% to ~8% with adjusted EPS of ~$11.10 to ~$11.30. Capital equipment is the cyclical part and moves with hospital budgets; AST moves with how many devices its customers actually manufacture, so a destocking cycle at a large device maker shows up in STERIS volumes with a lag. Cash generation is the quiet strength, with fiscal 2027 free cash flow guided near ~$800 million against gross debt of roughly ~$1.9 billion, or about ~1.1x EBITDA, leaving room for the ~$600 million chemistries plant announced in North Carolina, a fresh ~$1 billion buyback authorization and a dividend raised for a 21st consecutive year.

The bull case: what would have to be true for $280.00

The most optimistic published target on STE is $280.00, +17.1% from the $239.15 price as of August 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Recurring consumables and service, not equipment sales

Most of what STERIS books each quarter is not a machine. Consumables and service revenue attach to an installed base that hospitals cannot easily rip out, since sterilization workflows are validated, regulated and staff-trained around specific equipment. In the fiscal 2026 fourth quarter Healthcare service revenue grew ~9% and consumables ~7% while capital equipment grew ~6%, the pattern that lets reported growth hold up when hospital capital budgets tighten.

2. Outsourced sterilization volume tied to device manufacturing

AST is effectively a toll road for the medical device industry: manufacturers send product through STERIS facilities because building and validating sterilization capacity in-house rarely pays. Segment revenue reached ~$297.6 million in the fiscal 2027 first quarter, up ~6%, with service revenue carrying the growth. Capacity is geographically sticky, so incremental volume drops through at high margins once a plant is running.

3. Reinvestment into chemistries and consolidated manufacturing

Management committed roughly ~$600 million to a Formulated Chemistries Center of Excellence in North Carolina, phased across fiscal 2028 and fiscal 2029, alongside a targeted restructuring plan that consolidates existing chemistry sites. Company targets point to better than a ~10% return on invested capital within three to five years. Execution risk is real, and the market reaction to the announcement was mixed because the spending lands before the savings do.

4. Balance sheet capacity for tuck-in deals and buybacks

Gross leverage of about ~1.1x EBITDA is low for a healthcare industrial, and STERIS has historically used that room for acquisitions, Cantel Medical in 2021 being the largest. After divesting the Dental business, the company has directed capital toward its core three segments, a new ~$1 billion repurchase authorization and a quarterly dividend now at ~$0.69 per share.

The bear case: what would have to be true for $232.00

The most pessimistic published target is $232.00, -3.0% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks STERIS plc is worth if the risks below bite instead of the drivers above.

Ethylene oxide is the exposure that separates STERIS from an ordinary medical equipment name. Subsidiary Isomedix agreed to costs of up to roughly ~$48 million to resolve personal injury claims tied to an Illinois sterilization plant, and EtO emissions rules adopted by the EPA in 2024 remain in flux under reconsideration, which cuts both ways: looser rules reduce compliance capex, while continued legal uncertainty has already caused the company to hold off on some capacity expansion. Hospital capital spending is the second pressure point, since sterilizers and surgical tables are deferrable purchases when health systems face margin strain. AST volumes depend on customer manufacturing schedules rather than on STERIS decisions, so device industry destocking passes straight through. Tariffs and currency both moved reported results in fiscal 2026 and management flagged them again in the fiscal 2027 outlook. Valuation is itself a risk, because a high-twenties trailing multiple leaves little room for a guidance cut.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding STE already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on STE

8 analysts cover STE, with an average target of $263.12 (+10.0% against $239.15) and a split of 6 buy, 3 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the STE forecast and price target page.

How is STE valued? (as of August 2026)

Price

$239.15

Market cap

$23.32B

P/E (TTM)

29.24

Forward P/E

19.53

Price / book

3.24

Beta

0.91

52-week range

$195.14 to $269.44

Snapshot for STE as of August 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (TTM): ~$6.04 billion
Market cap: ~$23.2 billion at a share price near ~$239
Trailing P/E: ~29x on trailing EPS of ~$8.18
Forward P/E: ~21x on fiscal 2027 adjusted EPS guidance of ~$11.10 to ~$11.30
Dividend: ~$2.76 per share annualized, a yield near ~1.2%, raised for a 21st straight year
Leverage: ~$1.9 billion gross debt, roughly ~1.1x EBITDA

STERIS runs a March fiscal year, so the trailing twelve months as of August 2026 spans the final three quarters of fiscal 2026 plus the June 2026 quarter that opened fiscal 2027. Fiscal 2027 first quarter revenue rose ~7% to ~$1.5 billion with adjusted EPS of ~$2.59, and full-year guidance of ~7% to ~8% reported growth was reiterated. The gap between the ~29x trailing and ~21x forward multiple reflects both expected earnings growth of ~9% to ~11% and the sizeable adjustments, including amortization and restructuring, that separate GAAP EPS from the adjusted figure guidance is built on.

How do you decide if STE is a buy?

Rather than asking whether STE is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the bull case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold STE indirectly through an index or sector ETF before adding more.

What would change your mind on STE

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

Bull case breaks if: Recurring consumables and service, not equipment sales stalls in the reported numbers rather than in the narrative around them.
Bear case breaks if: ethylene oxide is the exposure that separates STERIS from an ordinary medical equipment name fails to materialise over several reporting periods while the drivers keep compounding.
Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the STE stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about STE against your real portfolio and see your actual exposure before deciding.

Investing in STERIS plc with AI

Connect the broker you already use and ask Walnut's AI how STE fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.

Does STE fit me?

FAQ

Is STE a good stock to buy right now?

That depends on which case you find more convincing, and both are on this page. The bull case rests on Recurring consumables and service, not equipment sales, with revenue (ttm) at ~$6.04 billion. The bear case rests on ethylene oxide is the exposure that separates STERIS from an ordinary medical equipment name. Analysts covering it are spread from $232.00 to $280.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Should I sell STE?

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Ethylene oxide is the exposure that separates STERIS from an ordinary medical equipment name. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $232.00, -3.0% from the $239.15 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

What is the bull case for STE?

Recurring consumables and service, not equipment sales. Most of what STERIS books each quarter is not a machine. The most optimistic analyst target on STE is $280.00, +17.1% from the $239.15 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for STE?

What does STERIS plc do?

STERIS makes sterilizers, surgical consumables and cleaning chemistries for hospitals, and runs contract sterilization plants for medical device makers.

What would have to change for STE to stop being worth holding?

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Recurring consumables and service, not equipment sales) stalling in the reported numbers rather than in the narrative, the risk above (ethylene oxide is the exposure that separates STERIS from an ordinary medical equipment name) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does STERIS actually sell?

Three related things. Sterilization and surgical equipment plus the consumables and service contracts that follow it into hospitals, contract sterilization of medical devices at STERIS-owned plants before those devices reach the market, and cleaning chemistries and validation services for pharmaceutical manufacturers. Healthcare is by far the largest of the three at roughly ~70% of revenue.

Is STERIS a US or an Irish company?

Both descriptions are partly right. STERIS plc is incorporated in Ireland, which is why the name carries plc, while operations are headquartered in Mentor, Ohio and the majority of revenue is generated in the United States. The shares are ordinary shares listed directly on the NYSE, not an ADR, and STE is an S&P 500 constituent.

When does STERIS report earnings?

STERIS runs a fiscal year ending March 31, so its quarters are offset from the calendar. Fiscal 2026 closed on March 31, 2026 and was reported in May 2026 with revenue of roughly ~$5.9 billion. The fiscal 2027 first quarter, covering April through June 2026, was reported on August 6, 2026.

Walnut is informational, not investment advice, and gives no verdict on STE. Analyst targets referenced here come from a August 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.